OvaScience Inc. (NASDAQ:OVAS)’s share price rose 3.7% on Tuesday . The company traded as high as $6.33 and last traded at $6.24, with a volume of 256,100 shares traded. The stock had previously closed at $6.02.

OVAS has been the topic of a number of research reports. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. JPMorgan Chase & Co. lowered their target price on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Leerink Swann reissued a “hold” rating and set a $7.00 target price (up from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. OvaScience currently has a consensus rating of “Hold” and an average target price of $11.64.

The stock’s market capitalization is $170.53 million. The stock’s 50 day moving average price is $5.36 and its 200-day moving average price is $7.07.

OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.16. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. During the same period in the prior year, the firm earned ($0.64) EPS. The business’s revenue for the quarter was up 530.0% on a year-over-year basis. On average, equities analysts predict that OvaScience Inc. will post ($2.98) EPS for the current fiscal year.

In other OvaScience news, CEO Michelle Dipp acquired 425,000 shares of the business’s stock in a transaction on Wednesday, June 1st. The stock was purchased at an average price of $7.00 per share, with a total value of $2,975,000.00. Following the acquisition, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at approximately $6,803,447. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard Aldrich acquired 36,095 shares of the business’s stock in a transaction on Friday, May 13th. The stock was acquired at an average cost of $6.94 per share, with a total value of $250,499.30. Following the acquisition, the director now directly owns 604,185 shares in the company, valued at $4,193,043.90. The disclosure for this purchase can be found here.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.